- Home
- PHLT vs DAWN Comparison
PHLT vs DAWN Comparison
Compare PHLT & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- DAWN
- Stock Information
- Founded
- PHLT 1976
- DAWN 2018
- Country
- PHLT United States
- DAWN United States
- Employees
- PHLT N/A
- DAWN N/A
- Industry
- PHLT Other Consumer Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- PHLT Consumer Discretionary
- DAWN Health Care
- Exchange
- PHLT Nasdaq
- DAWN Nasdaq
- Market Cap
- PHLT 601.2M
- DAWN 624.8M
- IPO Year
- PHLT N/A
- DAWN 2021
- Fundamental
- Price
- PHLT $7.63
- DAWN $7.55
- Analyst Decision
- PHLT Buy
- DAWN Strong Buy
- Analyst Count
- PHLT 2
- DAWN 7
- Target Price
- PHLT $7.88
- DAWN $27.86
- AVG Volume (30 Days)
- PHLT 1.6M
- DAWN 1.3M
- Earning Date
- PHLT 11-05-2025
- DAWN 10-29-2025
- Dividend Yield
- PHLT N/A
- DAWN N/A
- EPS Growth
- PHLT N/A
- DAWN N/A
- EPS
- PHLT N/A
- DAWN N/A
- Revenue
- PHLT $137,357,000.00
- DAWN $187,638,000.00
- Revenue This Year
- PHLT $12.38
- DAWN $12.56
- Revenue Next Year
- PHLT $10.09
- DAWN $48.02
- P/E Ratio
- PHLT N/A
- DAWN N/A
- Revenue Growth
- PHLT 15.21
- DAWN 2190.50
- 52 Week Low
- PHLT $2.17
- DAWN $5.64
- 52 Week High
- PHLT $7.74
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- PHLT 81.43
- DAWN 62.75
- Support Level
- PHLT $7.56
- DAWN $7.22
- Resistance Level
- PHLT $7.67
- DAWN $7.71
- Average True Range (ATR)
- PHLT 0.03
- DAWN 0.31
- MACD
- PHLT -0.14
- DAWN 0.06
- Stochastic Oscillator
- PHLT 63.64
- DAWN 82.95
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.